Test Your Hypothesis

 BGPT Odds of True

CD24 macrophage checkpoint and stage-dependent reversal are evidenced; the causal bridge (compensatory sialylation redirecting recognition from Siglec-10 to STAB1) is entirely untested and has no direct supporting data in any supplied record.

 Hypothesis Novelty

Linking glycan shield redistribution after CD24 loss to a STAB1/Siglec-10 receptor switch and using it to explain stage-specific prognosis is a genuinely novel synthesis not present in any supplied paper.

 Quick Analysis Plan Copied

 Long Analysis Plan

Evidence supporting the hypothesis components

The hypothesis has three components: (1) CD24 is a macrophage checkpoint; (2) CD24 loss triggers compensatory sialylation of other glycoproteins; (3) this reroutes recognition to STAB1-like scavenger receptors, explaining the stage-dependent prognostic reversal. Only (1) is directly supported.

CD24 macrophage checkpoint (supported): CD24 knockout in SW620 CRC cells increased zebrafish xenograft clearance ~4-fold (~70-80% vs ~20%, p<0.001), and clodronate-mediated macrophage depletion completely abolished this difference, confirming macrophage mediation CD24 checkpoint causal evidence. CD24 loss also increased macrophage motility and directionality toward tumors Macrophage motility after CD24 loss.

Prognostic reversal (supported): In TCGA (n=601), high CD24 predicted worse Stage I OS (p=0.011) and PFI (p=0.039, HR=6.74), but better Stage III OS (p=0.031, HR=0.50) and PFI (p=0.004, HR=0.41); no association in Stages II or IV Stage I/III CD24 reversal.

STAB1 efferocytosis axis (independently supported, but not linked to CD24): STAB1+ TAMs in COAD show elevated efferocytosis signaling (MERTK, AXL, TIMD4), mTORC1 activation, M2 polarization, and correlate with poorer prognosis STAB1+ TAM efferocytosis in COAD. However, this study never examined CD24 or compensatory sialylation.

Siglec-10 sialoglycan recognition (mechanistically relevant): Siglec-10 binds sialoglycans via dual arginine residues (R119, R127) and functions as an immune checkpoint Siglec-10 sialoglycan binding structure, and Siglec-10 ligand disruption enhances macrophage phagocytosis of tumor cells Siglec-10 blockade enhances phagocytosis.

Critical gaps and blindspots

• No evidence of compensatory sialylation: No supplied study measured glycome changes (e.g., by lectin arrays or glycoproteomics) after CD24 knockout. The sialylation-redirect hypothesis is a conjecture, not an observation.
• No evidence of STAB1 binding to sialylated ligands: STAB1 is a scavenger receptor with known ligands (e.g., Stabilin ligands, apoptotic cells), but the supplied records do not establish sialoglycan recognition by STAB1.
• Candidate receptor unvalidated: The CD24 study's own candidate receptor (si:dkey-24p1.7) awaits functional validation, and no Siglec-10/STAB1 perturbation was performed in the CD24-KO clearance experiments.
• Alternative explanations for the reversal: Stage III high-CD24 benefit could reflect confounding by adjuvant chemotherapy response, tumor-intrinsic differences (e.g., MSI status, differentiation), or microsatellite/TMB covariates — none addressed in the records. Stage-specific CD24 correlation with sialyltransferase expression (ST3GAL/ST6GAL families) was not measured.
• Zebrafish larvae lack adaptive immunity and STAB1 biology may differ from human TAMs; STAB1 in vitro work was primarily in mouse BMDMs STAB1 study limitations.

What would falsify or confirm

Falsification: show that CD24-KO CRC cells do NOT redistribute surface sialylation, or that sialylation blockade (e.g., ST3GAL/ST6GAL inhibition) does not alter macrophage clearance of CD24-KO cells, or that STAB1 blockade does not rescue CD24-independent clearance differences. Confirmation would require lectin/glycoproteomic profiling of CD24-KO vs WT SW620 membranes, STAB1-Siglec-10 dual blockade in macrophage co-culture, and sialyltransferase correlation analysis within TCGA Stage I vs III strata.

Confidence note: The hypothesis is creative and testable, but only its first premise (CD24 as a macrophage checkpoint) and its endpoint (stage-dependent CD24 prognostic reversal) are evidenced. The mechanistic bridge — compensatory sialylation rerouting recognition to STAB1 — remains speculative.